" class="no-js "lang="en-US"> Thermo Fisher Scientific - Pharmtech Focus
Thursday, January 26, 2023
Thermo Fisher Scientific | Pharmtech Focus

Thermo Fisher Scientific

About Thermo Fisher Scientific

Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.

Related Story

Thermo Fisher Scientific Launches CE-IVD Marked Assay to Detect Treatment-Resistant Strains of HIV-1

January 24 2023

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its […]

FDA Approves First NGS-based Companion Diagnostic to Aid in Selecting Non-small Cell Lung Cancer Patients With HER2 (ERBB2) Activating Mutations (SNVs & Exon 20 Insertions) for Treatment With ENHERTU

August 15 2022

The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific’s Oncomine […]

Moderna and Thermo Fisher Scientific Announce Long-term Strategic Collaboration

February 24 2022

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and […]

New Triple Wrapped Culture Media Plates for Environmental Monitoring Provide Advanced Sterility Assurance to Pharmaceutical Manufacturers

January 5 2022

Pharmaceutical manufacturers can now perform more confident, compliant environmental monitoring using culture media plates that […]

FDA Approves NGS-Based Companion Diagnostic for EGFR Exon20 Insertion Mutant Non-Small Cell Lung Cancer Tumor Tissue

December 10 2021

The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific‘s Oncomine Dx Target […]

Cellenion and Thermo Fisher Scientific Announce Partnership for Single Cell Mass Spectrometry-Based Proteomics Analysis

November 15 2021

Cellenion, a BICO company, announced today a co-marketing agreement with Thermo Fisher Scientific to advance single cell proteomics analyses. […]

FDA Approves Tissue-Based NGS Companion Diagnostic for Takeda's Targeted Therapy for NSCLC Patients with EGFR Exon20 Insertion Mutations

September 17 2021

The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific‘s […]

Thermo Fisher Scientific and AstraZeneca to Co-Develop NGS-based Companion Diagnostics

September 2 2021

Thermo Fisher Scientific‘s clinical sequencing business and AstraZeneca today announced they will co-develop next-generation sequencing […]